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The promyelocytic leukemia protein (PML) is the 
essential component of multi-protein sub-nuclear 
structures, the PML-Nuclear bodies (PML-NB, [1]). 
The PML-NBs regulate a variety of nuclear functions, 
including post-translational modifications in nuclear 
proteins (acetylation, SUMOylation, ubiquitylation) 
[1]. This function has led to the current notion that 
PML is a modulator of cell responses, which might 
not be essential in steady-state conditions (under lack 
of stress) but plays a critical role when the cell and 
organism is challenged. This notion is supported by 
the fact that the lack of PML in mice does not result in 
embryonic lethality or overt physiological alterations 
in adulthood, but it alters the response to oncogenic 
insults or dietary alterations [1-4].  
The activity of PML has been mostly investigat-
ed in the context of suppression, pathogenesis and 
progression of tumorigenesis. However, evidence of 
the function of this protein beyond malignant trans-
formation are quickly accumulating. We and others 
have recently reported that the expression of PML is 
relevant for the response to metabolic insults, nutri-
tional disorders and obesity [4-8]. In this study, we 
aimed at extending and defining the status of PML in 
conditions of nutritional challenge. To this end, we 
evaluated PML transcript abundance in a cohort of 
human liver biopsies from lean or morbidly obese 
subjects. Liver material from lean patients was ob-
tained from 3 subjects (3 women; age, 46±12 years; 
BMI, 21±2 kg/m²) undergoing partial hepatectomy for 
benign tumors (neighbor tissues from four adenoma 
and one focal nodular hyperplasia) and did not dis-
play any hepatic steatosis, inflammation or fibrosis. 
For obese patients, bariatric surgery was indicated in 
accordance with French guidelines (the study was 
approved by “Comité Consultatif de Protection des 
Personnes dans la Recherche Biomédicale de Nice” 
07/04:2003, N° 03.017) (Fig. 1A). Quantitative real 
time RT-PCR (q-RT-PCR) analysis (references from 
Applied biosystems Hs99999902_m1 for housekeep-
ing RPLP0 (Ribosomal protein, large subunit, P0) and 
Hs00231241_m1 for PML and as previously described [9, 
10]), revealed a significant PML up-regulation in 
obese individuals (Fig. 1B). Further, hepatic PML ex-
pression increased in obese patients without liver 
complications (n=5) versus lean subjects (+2.49±0.28, 
P=0.036). We next decided to extend this observation 









diet; LabDiet 5008 (Pharmaserv, Framingham, MA, 
USA) as chow, following the procedure in Ref. [11]) or 
genetic (Agouti mutant heterozygous) mouse models 
of obesity (the mouse experiments were approved by 
IACUC, USA). Q-RT-PCR analysis in high-fat diet fed 
mice demonstrated the up-regulation of Pml in livers 
from obese mice (murine Pml primers, Pml_F: 
GATCTCCGCGACAATTCAGT, Pml_R: ATGCCACT 
GCTGAATCTCCT; Cyclophilin was used as house-
keeping gene; Cyclo_F: GGTGGAGAGCACCAAG 
ACAGA, Cyclo_R: GCCGGAGTCGACAATGATG; 
Fig. 1C). Importantly, transcriptional up-regulation of 
this gene was accompanied by the detection of Pml 
immunoreactive nuclear bodies by immunohisto-
chemistry in <5% of hepatocytes in livers from HFD 
mice (using Millipore Pml antibody), but rarely in 
those from lean individuals (Fig. 1D), similar to our 
prior observations in another mouse model [4]. Of 
note, Pml immunoreactivity was often restricted to a 
single or few large nuclear bodies of doughnut shape, 
a structural conformation prior described for PML 
nuclear bodies. We also confirmed the increase Pml 
immunoreactivity in a second murine model of obe-
sity, driven by the heterozygous mutation in the 
Agouti gene (Jackson laboratory ref. KK.Cg-Ay/J; Ref. 
[12]; Fig. 1E).  
 
Figure 1. PML is up-regulated in hepatocytes from obese individuals. (A-B) Description of the clinical features of obese subjects (A) in which PML transcript 
abundance (q-RT-PCR) was measured (B). (C-D). Pml transcript abundance (q-RT-PCR) (C) and immunoreactivity (D) in mice subjected to standard (chow) or 
obesity-inducing high-fat diets (HFD) (representative micrographs from n=4-5; squares represent zoomed region; red arrows depict PML immunoreactive 
hepatocytes; red asterisks depict PML immunoreactive non-hepatocyte cells). **, p<0.01 calculated by non-parametric Mann-Whitney test. (E) Pml, Sumo-1 and 
Nucleophosmin (Npm) immunoreactivity in livers from wild type or agouti heterozygous mutant mice (representative micrographs from n=3; squares, arrows and 
asterisks as described in D).  





PML nuclear bodies are enriched in SUMO-1 
(Santa Cruz BioTechnology). Immunohistochemical 
analysis confirmed similar nuclear distribution of 
Sumo-1 into nuclear bodies at a similar rate of Pml, 
which strongly suggests that the staining of Pml cor-
responds to functional nuclear bodies (Fig. 1E). It is 
worth noting that this altered pattern of nuclear lo-
calization was not observed in other non PML-NB 
resident proteins such as nucleophosmin (a nucleolar 
protein; Cell Signaling Technology; Fig. 1E). In sum-
mary, our results demonstrate that PML accumulates 
in hepatocytes in conditions of obesity.  
Obesity is associated to lipid accumulation in 
hepatocytes, termed steatosis [13]. Since there are 
pathological conditions where steatosis can be trig-
gered in the absence of obesity, we sought to ascertain 
whether PML accumulation was related to obesity or 
it was a consequence of the steatosis associated to 
weight increase. To this end, we first evaluated PML 
expression in obese patients with different degree of 
steatosis (0, <5%; 1, 5%-30%; 2, >30%-60%; 3, >60%) 
[14]. The results clearly demonstrated that PML ex-
pression significantly correlated with the extent of 
steatosis (Fig. 2A).  
In addition, we took advantage of a dietary re-
gime that results in weight loss and liver lipid accu-
mulation, namely ketogenic diet (KD; Ref. Bio-Serv 
F3666, [11]). The results confirmed that Pml transcript 
and immunoreactivity were increased (Fig. 2B-C).  
Fatty liver disease is a rapidly increasing pa-
thology that, albeit tightly associated with obesity, is 
also observed in a fraction of lean individuals, where 
it is thought to be related to nutrition and life style 
factors [13]. Our results conclusively demonstrate that 
PML expression is increased in livers from obese in-
dividuals, and is particularly associated to a steatotic 
phenotype. These findings are of relevance for the 
characterization of PML non-tumoral functions. Im-
portantly, this observation might open an interesting 
mean of regulation of PML in the context of cancerous 
lesions, in which nutrient availability might impact on 
the expression of this protein and hence on the biol-
ogy of the disease. In particular, they extend our 
knowledge regarding the patho-physiological regula-
tion of PML in metabolism. In this respect, it is 
tempting to speculate that PML induction may rep-
resent a failsafe response to steatosis in view of the 
positive role it plays in the activation fatty acid oxi-
dation pathways [4, 5]. 
 
Figure 2. PML liver mRNA expression increases in steatosis. (A) PML mRNA expression (q-RT-PCR) in individuals with defined degree of liver steatosis; the 
correlation of PML and steatotic grade (S0-S3) was calculated by non-parametric Spearman test. (B-C) Pml transcript expression(q-RT-PCR) (B) and immunoreac-
tivity (C) in livers from mice subjected to chow or ketogenic diet (KD). Representative micrographs from n=4-5; squares represent zoomed region; red arrows depict 
PML immunoreactive hepatocytes; red asterisks depict PML immunoreactive non-hepatocyte cells **, p<0.01 calculated by non-parametric Mann-Whitney test. 
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